CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
BMS-663068 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01009814
NCT01009814Phase 2Completed
CompareCT.gov

Randomized, Open Label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects

ViiV Healthcare·interventional·Posted Nov 9, 2009·Updated Jan 3, 2020

In Brief

A Phase 2 clinical trial evaluating BMS-663068 and Ritonavir for HIV Infections. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Research Hypothesis: Administration of BMS-663068, a prodrug for HIV attachment inhibitor BMS-626529, will result in a mean decrease of at least 1 log10 in HIV RNA at Day 9 following 8 days of therapy in at least one dosing regimen that is safe and well tolerated in Clade B HIV-1 infected subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesGermany
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 9, 2009
Enrollment StartNov 23, 2009
Primary CompletionJun 25, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.6 years ago

Interventions

BMS-663068drug

BMS-663068 will be administered as a tablet formulation

Ritonavirdrug

Ritonavir will be administered as a capsule.